Last updated 2026-09-04
- Went public on TASE (CFBI), Sep 2005
- Raised $175M Follow-on PO, Oct 2005
- Raised $8M Follow-on PO, Apr 2026
Total raised
$247.3M
Last: Public Offering 2025-07
Stage
Public
Founded
1994
Headcount
5
HQ
Petah Tikva, Israel
Sector
Healthcare
Website ↗Registrar ID: 512022153 (Can-Fite BioPharma Ltd.)
About
Can-Fite BioPharma is an Israeli biopharmaceutical company with fully integrated pharmaceutical discovery and clinical development capabilities. The company has an advanced pipeline of proprietary drug candidates in Phase II and Phase III clinical development addressing oncology, inflammatory, and metabolic diseases. Can-Fite's platform technology utilizes the Gi protein associated A3 adenosine receptor (A3AR) as a therapeutic target, which is highly expressed in inflammatory, cancer, and other pathological cells, with low expression in normal cells.
Funding history · 14 rounds · $247.3M total
21 events/rounds · $247.3M Total Funding: $15.5M in Private Equity, $257.0M in Public Equity
Apr 2026
Follow-on PO
$8.0M
EDGAR filing SEC-EDGAR filing SEC-EDGAR
May 2025
Follow-on PO
$2.6M
EDGAR filing SEC-EDGAR filing SEC-EDGAR
Sep 2024
Follow-on PO
$4.5M
EDGAR filing SEC-EDGAR filing SEC-EDGAR
Nov 2023
Follow-on PO
$3.0M
EDGAR filing SEC-EDGAR filing SEC-EDGAR
Feb 2023
Follow-on PO
$7.5M
EDGAR filing SEC-EDGAR filing SEC-EDGAR
May 2019
Follow-on PO
$6.0M
EDGAR filing SEC-EDGAR filing SEC-EDGAR
Mar 2018
Follow-on PO
$5.0M
EDGAR filing SEC-EDGAR filing SEC-EDGAR
Oct 2015
Follow-on PO
$5.0M
EDGAR filing SEC-EDGAR filing SEC-EDGAR
Dec 2014
Follow-on PO
$8.0M
EDGAR filing SEC-EDGAR filing SEC-EDGAR
Feb 2013
★ Barak Capital Ltd.★ Menora Mivtachim Underwriting and Management Ltd.Roth Capital Partners LLCMeitav Issuing and Finance Ltd.Israeli, US and European investors
2007
Oct 2005
Jun 2002
★ Vitaife★ Giza Venture Capital★ some senior physicians★ BPW Israel Ventures LLD★ Ascend Technology Ventures
Mar 2001
Headcount over time
5 employees (2026-09) · 1 point
Offices
Petah Tikva, Israel · HQ / main office
Show all offices (1 more)
- Waltham, United States
Q&A
- What was Can-Fite BioPharma's most recent public offering?
- Can-Fite BioPharma had a Public Offering on July 28, 2025, raising up to $15.0 million.
- What recent patent allowance did Can-Fite BioPharma receive for its anti-obesity drug Namodenoson?
- In February 2026, Can-Fite BioPharma received a Canadian patent allowance for Namodenoson as an anti-obesity therapy.
- What is the status of Can-Fite BioPharma's Phase 2a pancreatic cancer study with Namodenoson as of July 2026?
- In July 2026, Can-Fite BioPharma's Phase 2a pancreatic cancer study with Namodenoson achieved its primary safety endpoint and demonstrated durable survival outcomes in advanced disease.
- What is the latest development regarding Can-Fite BioPharma's Piclidenoson for canine osteoarthritis?
- In March 2026, Can-Fite BioPharma's partner Vetbiolix completed enrollment in a Phase 2 osteoarthritis study in dogs treated with Piclidenoson, with data expected in Q3 2026.
- What was a significant clinical observation reported by Can-Fite BioPharma in June 2026?
- In June 2026, Can-Fite BioPharma reported a positive clinical observation in its Phase 2a pancreatic cancer study and highlighted Namodenoson’s RAS signaling inhibition mechanism.
- What is the current status of Can-Fite BioPharma's pivotal Phase 3 psoriasis study?
- In July 2026, Can-Fite BioPharma achieved a key pivotal Phase 3 psoriasis milestone with the completion of patient enrollment for the interim analysis, with data expected in Q4 2026/Q1 2027.
- What patent allowance did Can-Fite BioPharma secure in Japan for Namodenoson's anti-obesity technology?
- In June 2026, Can-Fite BioPharma secured a Japanese patent allowance for Namodenoson's anti-obesity technology.
- What was the outcome of Can-Fite BioPharma's Phase 2a pancreatic cancer study with Namodenoson reported in April 2026?
- In April 2026, Can-Fite BioPharma reported positive Phase 2a data with Namodenoson in pancreatic cancer, noting that 35% of patients remained on therapy, including one beyond 16 months.
Team · 10
Pnina Fishman
Founder · Executive Chairperson, CSO, Scientific Founder
Motti Farbstein
CEO, CFO
Guy Regev
Board of Directors
Yossi Bornstein
Board of Directors
Abraham Sartani
Board of Directors
Ilan Tamir
Board of Directors
William D. Kerns
VP Drug Development
Michael Silverman
Senior Medical Advisor
Zivit Harpaz
Director of Regulatory and Clinical Operations
Sari Fishman
Vice President of Business Development
Highlights
1 PatentsVerified
Tags
oncologycancerinflammatory-diseasesorphan-drugpharmaceuticalsautoimmune-diseasesbiopharmaceuticalmetabolic-diseasedoctorsdrug-discoverypharma-companiespatientsbiotechnologydrug-developmenthospitals
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | canfite.com |
|---|---|
| facebook.com/CanFiteBioPharma | |
| Wikidata | wikidata.org/wiki/Q30268871 |
Identifiers & details
| Legal name | Can-Fite BioPharma Ltd. |
|---|---|
| Founded | 1994-9 |
| Employees (exact) | 5 |
| Offices | Waltham |
| Market cap | $16.1M |
| Status reason | Public on TASE on Sep 2005;Public on NYSE on Jul 2025; |
| Wikidata QID | Q30268871 |
Acquisitions & public offerings
| Type | Date | Exchange | Ticker | Amount |
|---|---|---|---|---|
| IPO | 2005-09 | TASE | CFBI | |
| IPO | 2012-09 | NYSE American | CANF | |
| Public Offering | 2013-02 | TASE | CFBI | $7.2M |
| Registered Direct Offering | 2017-01 | NYSE MKT | CANF | $5.0M |
| Public Offering | 2020-02 | NYSE American | CANF | $5.0M |
| Registered Direct Offering | 2025-04 | NYSE American | CANF | $3.0M |
| Public Offering | 2025-07 | NYSE American | CANF | $5.0M |
Radar intelligence
Patents
| EPO | 63 |
|---|
Web history (Wayback)
| Domain | canfite.com |
|---|
Wikidata
| QID | Q30268871 |
|---|
Certificate / subdomain footprint
| Subdomains | 4 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 512022153 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה ציבורית |
| Incorporated | 1994-09-11 |
| Purpose | לעסוק בסוגי עיסוק שפורטו בתקנון |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2002 |
| Active charges / liens | 0 |
| Registry events | 0 |
| Registered address | ברקת 10 פתח תקווה |